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1. Introduction 
 
“Targeted clinical metabolomics” focuses on the analysis of pre-defined metabolites in 
biological samples (1, 2). The quantitative determination of several hundreds of metabolites 
in clinical trials generates a snapshot of the actual metabolic system permitting conclusions 
about nutritional habits, metabolic regulations and pathway connections (3, 4). This 
knowledge supports the understanding of diseases development and permits data-based 
hypotheses for disease risk factors and biomarkers, e.g. for non-fatty liver disease (5) or 
obesity (6). 
In the wide range of applicable analytical methods, liquid chromatography coupled to tandem 
mass-spectrometry (LC-MS/MS) provides a powerful tool to determine this wide range of 
metabolites. Sample are prepared in a short time without extraction or derivatization 
procedures which are often necessary for other methods like gas chromatography (GC) or 
ultra-violet detection (UV) (7). Since LC-MS/MS can be used for sensitive analysis of a wide 
range of analytes (8), a metabolomics platform was established in the Division of Metabolic 
and Nutritional Medicine at the Dr. von Hauner Children’s Hospital. Utilizing the power of LC-
MS/MS, several methods were developed to determine amino acids (AA) (9), 
glycerophospholipid species (10), creatinine (11) as well as folate metabolites (12) and a 
shotgun MS/MS method to analyze several lipid species. The LC-MS/MS methods were 
implemented in addition to GC methods for the analysis of fatty acids (FA) (13). 
Within the metaboliomic platform, one objective of the presented dissertation was to expand 
the metabolomics platform by implementing applications for characterization of further 
disease risk factors. Precisely, class-specific methods were developed for nonesterified fatty 
acids (NEFA) and sulphur-containing AA, homocysteine (Hcy), cysteine (Cys) and 
methionine (Met). 
Sulphur-containing AA play a relevant role, both as methyl donators for the synthesis of 
different biological compounds (e.g. neurotransmitter, DNA) and as precursor for proteins or 
glutathione, which is essential for detoxication, modulation of the red-ox status and immune-
modulation (14, 15). Dysregulation of sulphur amino acids is associated with nutritional 
aspects and genetic factors (16, 17).  
Lower intake of folate and elevated Hcy concentrations are associated with increased 
cardiovascular disease (CVD) mortality (18, 19), increased incidence of dementia and 




    
Hcy is a potential biomarker for nutritional deficiency or cognitive function and is additionally 
a potential risk factor for CVD. Thus, Hcy measurement is routinely used in clinical 
laboratories. 
Previous methods used expensive enzyme- and immunoassays (22), HPLC methods using 
UV, fluorescence, or electrochemical detection (23) and GC- MS methods (24, 25) for Hcy 
determination. In recent years, LC-MS/MS methods were established for Hcy analysis (26-
28) providing more specificity, elevated sensitivity and improved cost-efficiency by decreased 
run time and less solvent consumption (29). The previous LC-MS/MS methods achieved 
cycle times about 3-4 minutes. One reason for the very short run time is the almost non-
existent or low retention of Hcy on reversed phase columns. But remaining adequate 
retention is an important factor in LC optimization to separate the analyte from interfering 
substances, which naturally exist in biological matrices like urine or blood plasma (30). These 
substances cause matrix effects with lower (ion-suppression) or higher response (co-
elutions) as expected by the calibration curve which is normally calculated with aqueous 
standards (31). 
Thus, one aim of the presented dissertation was to establish a robust method not only for 
Hcy but also for Cys and Met analysis using a special chromatography system to achieve an 
increase in retention time and avoid matrix effects. An additional determination of Met and 
Cys supports the identification of causal mechanisms of hyperhomocysteinemia more 
accurately, as the sulphur amino acids undergo an interrelated metabolism (18). The method 
will be especially applied to trials studying the effect of folate as well as vitamin B2 
supplementation on Hcy levels and cognitive functions. Thus, the application will support the 
understanding of Hcy as nutritional marker as well as biomarker. 
A further class of metabolites, which have a strong potential as marker for nutrition and as 
risk factor for the development of diseases, are nonesterified fatty acids (NEFA). NEFA are 
highly associated with various diseases like obesity (32), insulin resistance (33), diabetes 
(34), metabolic syndrome (35), adrenoleukodystrophy (36), Alzheimer’s disease or 
schizophrenia (37). NEFA are involved in the link of obesity, insulin resistance and diabetes 
contributing to lipotoxicity by affecting insulin sensitivity and ß-cell function (38). Single NEFA 
species may be more accurate and sensitive to identify biomarker and describing metabolic 
process than determination of total NEFA (39). Yang et al. identified 10 relevant lipid species 
as biomarkers of type 2 diabetes (T2DM), including nonesterified oleic acid (18:1), 
eicosapentaenoic acid (20:5) and docosahexaenoic acid (DHA, 22:6) (40). Furthermore, 
palmitic acid (16:0), stearic acid (18:0) and oleic acid were found to be suitable to reflect 




    
accumulation of polyunsaturated fatty acids (18:2 n6, 18:3 n3, 22:4 n6) and a lower pool of 
saturated fatty acids (12:0,14:0, 16:0, 17:0) in plasma of patients with metabolic syndrome 
(35). To unravel the mechanisms of lipotoxicity and the influence on metabolomic functions, 
the LIPID MAPS Consortium established a widespread lipidomics platform (42). Regarding 
this platform, all lipid classes, except NEFA, are measured with LC-MS/MS applications (43). 
NEFA are traditionally determined with GC methods which are used in routine procedures for 
analysis of NEFA with excellent chromatographic resolution but utilizing extraction and 
derivatization procedures to enhance volatility (39, 44). 
Considering the simplicity of sample preparation for LC-MS/MS, the lack of methods for 
determination of NEFA in human plasma by LC-MS/MS is quite remarkable. A problem in 
MS/MS determination of NEFA is their poor fragmentation (45). Post-column addition of 
cations (46, 47) or derivatization procedures (48, 49) improve fragmentation behavior, but 
provide additional preparation steps, which result in prolonged sample preparation 
procedures. Thus, one objective of the presented dissertation was to develop a 
comprehensive method for quantification of NEFA in human plasma. This method should 
avoid extraction and derivatization procedures to enable a cost-effective and fast 
determination of NEFA in clinical trials and cohort studies. 
One reason for the development of the NEFA method is the strong relation of NEFA to 
adipose tissue (AT) fatty acids, as NEFA are mainly generated by lipolysis of triacylglycerols 
(TAG) in AT during fasting. AT is an accepted long-term biomarker for the assessment of 
dietary fatty acid (FA) intake (50, 51). Furthermore, FA composition of AT is of special 
interest for disease progress and prediction, as alterations in AT fatty acid composition play a 
crucial role in the development of obesity (50). Different studies have been accomplished to 
analyze the influence of AT to obesity with inconsistent results (52-54). Hence, further 
investigations of AT fatty acid composition are required to determine the molecular switch of 
obesity to insulin resistance manifesting finally in T2DM. 
Despite the potential of adipose tissue FA, determination of AT composition is not feasible, 
as an invasive biopsy is required. This biopsy is not always practicable in large clinical trials. 
Therefore, samples of AT are often not available, and the implementation of a surrogate 
marker is needed. A close correlation between the surrogate marker and AT FA composition 
would enable less-invasive sample collection for patients. This is particular in patients, e.g. 
children, in whom it is difficult to perform an AT biopsy. This surrogate marker can be 




    
Despite the important relationship between NEFA and AT, less comprehensive in-vivo 
studies were accomplished. Most studies focused on single pathway steps, like release of 
NEFA from AT (55, 56) or (re-)uptake of NEFA to AT (57-59). 
Since, to our knowledge, only Yli-Jama et al. investigated the relation of AT to plasma NEFA 
in a comprehensive work (60), a further aim of this dissertation was to investigate the 
association of NEFA composition with AT FA composition to evaluate if NEFA may provide a 
potential surrogate marker for AT FA. Additionally to previous studies, we focused on the 
influence of BMI and AT site on the relation of plasma NEFA and AT FA composition. 
In this study, TAG of AT were analysed by hydrolysis of TAG species in three FA and 
glycerol. Afterwards, the released FA were determined with the same analytical method used 
for NEFA analysis. The FA composition of AT was determined without regarding exact 
structures of lipid species. 
Besides the measurement of the FA composition, other approaches exist to determine TAG 
and the other acylglycerol classes, diacylglycerols (DAG) and monoacylglycerols (MAG). 
Summarized, three different strategies were implemented. First, enzymatic and radiometric 
assays were implemented for measurement of total TAG and DAG (61). As second approach 
for acylglycerol determination, GC applications were developed to analyse the fatty acid 
content in the classes of tri- and diacylglycerol, usually in combination with thin-layer 
chromatography. The last strategy is the identification of exact acylglycerol species. With this 
approach, the correct position of FA in the TAG structure was determined by the different 
chromatographic and fragmentation behaviour of TAG in LC-MS/MS applications. 
Especially focusing on obesity, insulin resistance and diabetes, all of the three presented 
strategies have been used to analyse acylglycerols, because excess availability of TAG (34) 
and DAG (62) to insulin-sensitive tissue, like the liver, may be a key predictor for the 
development of insulin resistance. Correlation between total TAG and type 2 diabetes (61, 
63), obesity and insulin resistance (34) has widely been studied. More detailed applications 
look for relations between FA content and fasting insulin and glucose levels (64). In recent 
works, TAG species were found as more precise markers for insulin resistance compared to 
total TAG (65). This importance of exact acylglycerol species is highlighted by other studies 
(66, 67). But this approach is solvent- and time-consuming. The last objective of the 
presented dissertation was to review the advantages and disadvantages of the different 
strategies for acylglycerol analysis and to assess the need to develop an LC-MS/MS 
application for the DAG and TAG regarding the already established GC method for 




    
 
The key objectives of this work are as follows: 
 
• Development of a LC-MS/MS method for high-throughput analysis of sulfur-containing AA 
in plasma. 
• Development of a LC-MS/MS method for high-throughput analysis of NEFA concentrations 
and composition in plasma. 
• Evaluation of the relation of plasma NEFA and adipose tissue fatty acid composition. 
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For “Targeted clinical metabolomics” several metabolites are determined in large 
cohort trials or intervention studies to describe metabolic pathways and unravel 
metabolic disorders aiming at the identification of biomarkers and disease risk 
factors. For this purpose, laboratory methodology is needed, which provides fast and 
less cost-expensive analysis. Liquid chromatography coupled to triple quadrupole 
mass spectrometry (LC-MS/MS) technology meets these expectations and 
additionally facilitates analysis with high specificity and sensitivity. Thus, a LC-MS/MS 
metabolomics platform was established at the division of metabolic and nutritional 
medicine of the Dr. von Hauner Children’s Hospital of the LMU Munich, measuring 
phospholipids, acylcarnitines, amino acids (AA) and folate metabolites in addition to 
routinely used of fatty acids (FA) by gas chromatography (GC). 
The objective of this work was to expand this platform and to develop class-specific 
high throughput methods which enable simple, precise and inexpensive analysis of 
nonesterified fatty acids (NEFA) and sulphur-containing AA. While the AA are related 
to nutritional folate deficiency, cognitive dysfunction and cardiovascular risk, NEFA 
are key metabolites in the development of obesity and diabetes. Furthermore, the 
relation of NEFA and adipose tissue (AT) composition was determined to investigate 
the potential of NEFA to act as surrogate marker for AT FA to avoid invasive 
biopsies. 
Different strategies for acylglycerol analysis were reviewed to assess the need to 
develop a LC-MS/MS application for the di- and triacylglycerols (TAG) regarding the 
already established GC method for measurement of FA composition. 
 
Methods 
LC-MS/MS analysis of sulphur-containing AA was accomplished utilizing simple 
protein precipitation, including reduction of all homocysteine forms to free 
homocysteine, as well as aqueous normal phase (ANP) chromatography to increase 
the retention time aiming for a better separation from matrix and co-eluents. 
For NEFA analysis, a sample preparation was utilized avoiding cumbersome and 




    
to achieve short run time combined to good resolution, coupled to LC-MS/MS 
detection. 
Additionally, the implementation of qualifier ions supported the correct determination 
of NEFA and sulphur-containing AA. 
Relation of NEFA and AT FA composition was investigated in 27 donors of paired 
visceral (vAT) and subcutaneous abdominal AT (sAT) samples as well as plasma 
samples, who underwent abdominal surgery for weight reduction. Spearman 




The developed application for sulphur-containing AA allowed sensitive quantification 
of Hcy, Met and Cys. 
The new developed method for comprehensive NEFA analysis facilitates accurate 
quantification of 36 NEFA species in healthy human plasma. 
Both method validations showed high precision (CV <10%,<15%) and accuracy (90-
110%,80-120%) for determination of sulphur AA and NEFA, respectively. 
The use of qualifier ions supported unequivocal analyte verification, whereby co-
eluents were identified for both classes which was assisted, for sulphur AA, by the 
enhanced retention of using ANP chromatography. 
For both applications, sample preparation requires small sample volume (20µl) and 
short analysis time (<15 min per sample). 
Relations between AT FA and NEFA were studied for 42 FA. The correlations of 
NEFA and AT FA percentages varied widely between FA. Strong correlations 
between NEFA and sAT/vAT were found for odd-chain FA 15:0 (r=0.838/0.862), 17:0 
(0.839/0.833), 17:1 (0.667/0.735), 19:0 (0.658/0.739), 19:1 (0.779/0.744) and 19:2 
(0.803/0.560) as well as for omega-3 FA 22:6 (0.719/0.535). 
 
Conclusion 
The developed LC-MS/MS methods permit an efficient quantification of Hcy, Cys and 
Met as well as a comprehensive determination of NEFA in human plasma. The 
reproducibility and accuracy of both methods are comparable to previous methods, 





    
With the smaller sample volume and reduced total analysis time, compared to 
previous methods, the methods are well suited for high-throughput analysis. This 
enables application in clinical trials with high sample number which have to be 
analysed in short time and with low costs. In addition, the usage of 20µl plasma 
facilitates application in studies with children or adolescents, when blood is obtained 
by finger sticks or heel pricks. 
The relevance of the developed comprehensive NEFA application was shown in a 
study investigating the relation between NEFA in plasma and AT FA. In this study, 
NEFA groups like odd-chain or very long-chain FA, which were rarely analysed 
previously, showed different behaviour compared to other NEFA. For the FA content 
of TAG in adipose tissue, odd-chain FA and long-chain omega-3 FA in the NEFA 
fraction could serve a surrogate marker in fasted plasma enabling a virtual adipose 
tissue biopsy for these FA. Furthermore, these NEFA might act as biomarker for 
long-term dietary intake of dairy products and sea fish or fish oil. The lower 
correlation for some NEFA species with adipose tissue FA indicates that adipose 
tissue is not the only quantitatively important compartment affecting the concentration 
and composition of NEFA in the fasted state.  
For TAG analysis, LC-MS/MS application also provides a powerful possibility for 
identification and quantification of exact molecular acylglycerol species which is 
important to unravel molecular mechanisms. Nevertheless, the choice of technique 
strongly depends on the research questions, as FA composition, determined by GC, 
enables analysis of ω-FA and less abundant FA. Thus, LC-MS/MS applications are 
not necessarily superior to GC and time- and cost-consumption should be weighed 
up against possible advantages when developing a new LC-MS/MS approach for 








Unter „Targeted clinical metabolomics“ versteht man die Bestimmung verschiedener 
Stoffwechselmetabolite in Blutplasma oder Urin klinischer Studien. Das Ziel dabei ist 
es, Stoffwechselwege zu beschreiben und Störungen im Stoffwechsel aufzuklären, 
um Biomarker bzw. Risikofaktoren zu identifizieren. 
Für dieses Vorgehen werden Verfahren benötigt, die eine schnelle und 
kostengünstige Analyse ermöglichen. Liquid Chromatographie gekoppelt mit 
massenspektrometrischer Detektion (LC-MS/MS) erfüllt diese Kriterien und liefert 
zusätzlich Ergebnisse mit hoher Spezifität und Selektivität. Aus diesem Grund wurde 
in der „Abteilung für Stoffwechsel- und Ernährungmedizin“ im Dr. von Haunerschen 
Kinderspital eine LC-MS/MS-Metabolomics-Plattform installiert. Hierbei werden 
Phospholipide, Acylcarnitine, Aminosäuren (AA) und Folatmetabolite gemessen, 
zusätzlich zu den routinemäßig per Gaschromatographie (GC) bestimmten 
Fettsäuren (FA). 
Ziel der vorliegenden Dissertation war es diese Plattform zu erweitern und weitere 
Methoden zu entwickeln, die die Bestimmung von anderen Metabolitengruppen 
ermöglichen. Deshalb sollten einfache, präzise und günstige Methoden zur Messung 
von nicht-veresterten Fettsäuren (NEFA) und Sulfur-haltigen AA  entwickelt und 
validiert werden. Sulfur-AA stehen in Zusammenhang mit mangelhafter 
Folataufnahmen, kognitiver Fehlfunktion und kardiovaskulärem Risiko, während 
NEFA eine Schlüsselrolle in der Entwicklung von Adipositas und Diabetes 
einnehmen.  
Des Weiteren wurde die Korrelation zwischen der Fettgewebszusammensetzung und 
NEFA in Plasma bestimmt, um die Rolle von NEFA als Ersatzmarker für das 
Fettgewebe (AT) zu untersuchen, so dass aufwändige Fettgewebsbiopsien 
vermieden werden können. 
Als letzter Punkt wurden verschiedene Möglichkeiten zur Bestimmung von 
Glycerolen diskutiert, um den Nutzen der Neuentwicklung einer LC-MS/MS 






    
Methoden 
Die Analyse von Sulfur-AA per LC-MS/MS wurde mit Hilfe von einfacher 
Probenvorbereitung und Aqueous Normal Phase (ANP) Chromatographie 
durchgeführt. ANP Chromatographie ermöglicht einen Anstieg der Retentionszeit und 
damit verbunden eine Abtrennung des Homocystein von Co-Eluenten und anderen 
Matrixkomponenten. 
Für die Analyse von NEFA wurde auf die sonst nötigen bzw. üblichen Extraktions- 
und Derivatisierungsverfahren verzichtet, um Zeit und Lösungsmittel zu sparen. 
Ultra-performance LC (UPLC) wurde verwendet, um kurze Laufzeiten in Kombination 
mit guter Auflösung zu erhalten. 
Zusätzlich wurden Qualifier Ions eingeführt, um die korrekte Bestimmung der NEFA 
und der Sulfurhaltigen-AA zu unterstützen. 
Der Zusammenhang zwischen Fettgewebszusammensetzung und NEFA wurde mit 
Hilfe von Probentripplets von 27 Probanden bestimmt, die sich einer abdominalen 
Operation zur Gewichtsreduktion unterzogen. Von diesen Probanden wurde 
subkutanes Fettgewebe (sAT), abdominales Fettgewebe (vAT) und Blutplasma 
entnommen. Um den Zusammenhang zwischen AT und NEFA zu beschreiben, 
wurden Spearmans Rangkorrelationskoeffizienten bestimmt. 
 
Ergebnisse 
Die neu entwickelte Methode zur Bestimmung von Suflur-haltigen AA erlaubt die 
Quantifizierung von Homocystein, Methionin und Cystein. 
Die neu entwickelte Methode zur NEFA Messung ermöglicht es, 36 verschiedene 
NEFA Spezies zu quantifizieren.  
Beide Methoden (Sulfur-AA/NEFA) zeigten in der Validierung eine hohe Präzision 
(CV <10%/<15%) und Genauigkeit (90-110%/80-120%). 
Mit Hilfe von Qualifier Ions wurde die Analytenidentifizierung verbessert und es  
wurden Co-Eluenten sowohl für Sulfur-AA als auch NEFA identifiziert. Bei der 
Bestimmung der Sulfur-AA wurde die Identifikation von Co-Eluenten durch die 
verlängerte Retention der Analyten in der ANP Chromatographie unterstützt. 
Beide entwickelten Methoden benötigen nur geringe Mengen an Probenvolumen 
(20µl) und eine kurze Probenvorbereitungszeit. 
Der Zusammenhang zwischen AT und NEFA wurde für 42 FA untersucht. Starke 




    
(r=0.838/0.862), 17:0 (0.839/0.833), 17:1 (0.667/0.735), 19.0 (0.658/0.739), 19:1 
(0.779/0.744) und 19:2 (0.803/0.560) sowie omega-3 FA 22:6 (0.719/0.535)  
gefunden, während andere FA niedrigere Korrelationen zeigten.  
 
Schlussfolgerungen 
Die entwickelten LC-MS/MS Methoden ermöglichen eine effiziente Quantifizierung 
von Homocystein, Methionin und Cystein sowie eine umfassende Bestimmung von 
NEFA in menschlichem Blutplasma. Die Reproduzierbarkeit und die Richtigkeit 
beider Methoden sind vergleichbar mit älteren Methoden. Die Einführung von 
Qualifier Ions verbesserte allerdings die korrekte Identifizierung der analysierten 
Metaboliten im MS. 
Da weniger Probenvolumen benötigt wird und die gesamte Analysendauer im 
Vergleich zu vorherigen Methoden reduziert wurde, eignen sich beide Methoden für 
high-throughput Analysen. Dadurch ist eine Anwendung in größeren klinischen 
Studien möglich, in denen eine große Anzahl an Proben in kürzester Zeit und mit 
wenig Kosten analysiert werden müssen. Des Weiteren können die entwickelten 
Methoden aufgrund des geringen Probenvolumens auch in klinischen Studien 
angewendet werden, in denen Blut mit Hilfe von Finger- oder Fersenstiche gewonnen 
wird. 
Die Anwendung der neu entwickelten NEFA Methode für die Untersuchung zum 
Zusammenhang zwischen AT FA und NEFA im Plasma unterstrich die Bedeutung 
einen umfassenden Bestimmung von NEFA im Plasma, da NEFA Gruppen, wie 
ungeradkettige oder sehr langkettige FA, die in anderen Methoden selten bestimmt 
werden, ein andere Verhalten zeigten als andere NEFA Gruppen. 
Für den Gehalt von ungeradkettigen FA und langkettigen omega-3 FA im 
Fettgewebe, können NEFA in Nüchternplasma als Ersatzmarker herangezogen. Des 
Weiteren können diese NEFA als Marker für die Nahrungsaufnahme von 
Milchprodukten und Seefisch sowie Fischöl genutzt werden. Die niedrige Korrelation 
von einigen FA zwischen NEFA im Nüchternplasma und FA im AT lässt darauf 
schließen, dass nicht nur das Fettgewebe die Zusammensetzung der NEFA im 
Plasma bestimmt, sondern auch andere Gewebe und Faktoren einen Einfluss auf die 
Variation von NEFA im Nüchternzustand haben.  
Für die Anaylse von Acylglycerolen stellen LC-MS/MS Metthoden ebenfalls eine 




    
Acylglycerole bestimmt werden kann, was bei der Aufklärung von molekularen 
Stoffwechselvorgängen von Bedeutung ist. Allerdings hängt die Auswahl des 
benutzten Analysesystems stark von der Fragestellung der jeweils vorliegenden 
Studie ab. GC ermöglicht die Bestimmung von sehr niedrig konzentrierten FA in 
Acylglycerolen und die Trennung von omega FA, im Gegensatz zu LC-MS/MS. 
Daher sind LC-MS/MS Methoden nicht zwangsläufig den GC Methoden überlegen 
und der Aufwand von Lösungsmitteleinsatz und Entwicklungszeit für eine neue LC-
MS/MS Methode sollte sorgfältig gegen die Vorteile der Bestimmung der 
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